BeiGene Management
Management criteria checks 2/4
BeiGene's CEO is John Oyler, appointed in Jan 2010, has a tenure of 14.83 years. total yearly compensation is CN¥134.33M, comprised of 4.6% salary and 95.4% bonuses, including company stock and options. directly owns 3.52% of the company’s shares, worth $711.85M. The average tenure of the management team and the board of directors is 2.5 years and 4.3 years respectively.
Key information
John Oyler
Chief executive officer
CN¥134.3m
Total compensation
| CEO salary percentage | 4.6% |
| CEO tenure | 14.8yrs |
| CEO ownership | 3.5% |
| Management average tenure | 2.5yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
BeiGene: TEVIMBRA European Push Continues With Positive CHMP Opinion
Nov 06BeiGene: Poised For Re-Rating As BTKi Sales Show Strong Beat
Aug 22Analysts Just Made An Incredible Upgrade To Their BeiGene, Ltd. (NASDAQ:BGNE) Forecasts
Aug 14
BeiGene, Ltd. (NASDAQ:BGNE) Shares Fly 27% But Investors Aren't Buying For Growth
Aug 09BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)
Jun 21We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation
May 30Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?
Apr 21BeiGene Still Bleeding Red Ink Despite Blockbuster Drug
Mar 08BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price
Jan 31Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money
Oct 16Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation?
Jul 11Rock star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt
Jun 19Revenues Not Telling The Story For BeiGene, Ltd. (NASDAQ:BGNE)
Apr 17A Look At The Fair Value Of BeiGene, Ltd. (NASDAQ:BGNE)
Mar 24CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -CN¥6b |
| Jun 30 2024 | n/a | n/a | -CN¥4b |
| Mar 31 2024 | n/a | n/a | -CN¥6b |
| Dec 31 2023 | CN¥134m | CN¥6m | -CN¥6b |
| Sep 30 2023 | n/a | n/a | -CN¥7b |
| Jun 30 2023 | n/a | n/a | -CN¥13b |
| Mar 31 2023 | n/a | n/a | -CN¥13b |
| Dec 31 2022 | CN¥124m | CN¥6m | -CN¥14b |
| Sep 30 2022 | n/a | n/a | -CN¥15b |
| Jun 30 2022 | n/a | n/a | -CN¥14b |
| Mar 31 2022 | n/a | n/a | -CN¥12b |
| Dec 31 2021 | CN¥106m | CN¥5m | -CN¥9b |
| Sep 30 2021 | n/a | n/a | -CN¥9b |
| Jun 30 2021 | n/a | n/a | -CN¥9b |
| Mar 31 2021 | n/a | n/a | -CN¥8b |
| Dec 31 2020 | CN¥94m | CN¥5m | -CN¥11b |
| Sep 30 2020 | n/a | n/a | -CN¥10b |
| Jun 30 2020 | n/a | n/a | -CN¥10b |
| Mar 31 2020 | n/a | n/a | -CN¥8b |
| Dec 31 2019 | CN¥88m | CN¥5m | -CN¥7b |
| Sep 30 2019 | n/a | n/a | -CN¥6b |
| Jun 30 2019 | n/a | n/a | -CN¥5b |
| Mar 31 2019 | n/a | n/a | -CN¥5b |
| Dec 31 2018 | CN¥192m | CN¥4m | -CN¥5b |
| Sep 30 2018 | n/a | n/a | -CN¥3b |
| Jun 30 2018 | n/a | n/a | -CN¥2b |
| Mar 31 2018 | n/a | n/a | -CN¥923m |
| Dec 31 2017 | CN¥67m | CN¥3m | -CN¥606m |
Compensation vs Market: John's total compensation ($USD18.54M) is above average for companies of similar size in the US market ($USD12.67M).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
CEO
John Oyler (56 yo)
14.8yrs
Tenure
CN¥134,331,046
Compensation
Mr. John V. Oyler Co-Founded BeiGene, Ltd. and has been its Chief Executive Officer since 2010. Mr. Oyler Co-founded BioDuro, LLC and served as its Chief Executive Officer and President from 2005 to 2009....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 14.8yrs | CN¥134.33m | 3.52% $ 711.8m | |
| President & COO | 6.5yrs | CN¥78.08m | 0.056% $ 11.2m | |
| Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder | 14.8yrs | CN¥31.35m | 0.83% $ 167.0m | |
| General Counsel & Senior VP | 2.3yrs | CN¥28.74m | 0.017% $ 3.5m | |
| Global Head of R&D | no data | CN¥51.93m | 0.13% $ 26.1m | |
| CFO & Principal Financial Officer | less than a year | no data | no data | |
| VP & Chief Accounting Officer | less than a year | no data | 0.0033% $ 676.0k | |
| Head of Investor Relations | no data | no data | no data | |
| Chief Compliance Officer | 1.1yrs | no data | no data | |
| Senior VP & Head of Public Affairs - Greater China | 3.8yrs | no data | no data | |
| Senior Vice President of Strategic Partnership | no data | no data | no data | |
| Senior VP & Chief Medical Officer for Solid Tumors | 2.8yrs | no data | no data |
2.5yrs
Average Tenure
53.5yo
Average Age
Experienced Management: BGNE's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 14.1yrs | CN¥134.33m | 3.52% $ 711.8m | |
| Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder | 8.8yrs | CN¥31.35m | 0.83% $ 167.0m | |
| Acting Head of Medicinal Chemistry & Member of Scientific Advisory Board | 3.6yrs | no data | no data | |
| Independent Non-Executive Director & Member of the Scientific Advisory Committee | 9.6yrs | CN¥3.42m | 0.0034% $ 684.1k | |
| Independent Non-Executive Director & Member of Scientific Advisory Committee | 4.3yrs | CN¥3.56m | 0.0022% $ 437.2k | |
| Independent Non-Executive Director | 4.8yrs | CN¥3.64m | 0.0027% $ 548.5k | |
| Director | less than a year | no data | no data | |
| Co-Chairman of Scientific Advisory Committee & Independent Non-Executive Director | 2.8yrs | CN¥3.49m | 0.0021% $ 433.2k | |
| Independent Non-Executive Director | less than a year | no data | 0% $ 0 | |
| Independent Lead Director | 10.1yrs | CN¥3.46m | 0.0034% $ 684.1k | |
| Member of Scientific Advisory Board & Independent Non-Executive Director | 2.8yrs | CN¥3.62m | 0.0021% $ 433.2k |
4.3yrs
Average Tenure
62yo
Average Age
Experienced Board: BGNE's board of directors are considered experienced (4.3 years average tenure).